Empator L 25mg/5mg Tablets (14s)

Description

Empator L is a prescription combination medicine containing empagliflozin and linagliptin for improving blood-glucose control in adults with type 2 diabetes. It is used together with diet and exercise and is supplied as a pack of 14 tablets.

• Manufacturer Name: Martin Dow
• Drug Class: Antidiabetic combination: SGLT2 inhibitor and DPP-4 inhibitor
• Dosage Form: Tablet
• Storage: Store at room temperature in a dry place, protected from heat, moisture, and direct light. Keep out of reach of children and retain in the original packaging.
• Pack Size: Pack of 14 Tablets

Empator L 25mg/5mg Tablets (14s) Available Online in Pakistan

Dwatson offers Empator L 25mg/5mg Tablets (14s) at Rs. 728, with fast, discreet delivery across Pakistan.

Ingredients

• Empagliflozin 25 mg
• Linagliptin 5 mg

Benefits

• Improves blood-glucose control in adults with type 2 diabetes mellitus.
• Used as an adjunct to diet and exercise.
• May be used alone or with other glucose-lowering medicines when prescribed by a healthcare professional.

Usage & Safety

For Adult

• The usual dose is one tablet once daily, taken at approximately the same time each day.
• May be taken with or without food and swallowed whole with water.
• Maintain adequate fluid intake unless fluid restriction has been advised.
• Dosage and suitability should be assessed by a physician, particularly in patients with impaired kidney function or those taking insulin or sulfonylureas.

For Children

• Not recommended for children and adolescents under 18 years because safety and efficacy have not been adequately established.
• No pediatric weight-based dose is established for this combination.

Side Effects

• Common effects may include increased urination, thirst, genital yeast infection, urinary tract infection, and mild gastrointestinal symptoms.
• Low blood sugar may occur, particularly when used with insulin or sulfonylureas.
• Serious warning signs include severe dehydration, dizziness or fainting, reduced urine output, severe abdominal pain, persistent vomiting, breathing difficulty, confusion, or unusual tiredness.
• Seek urgent care for symptoms of ketoacidosis, severe allergic reaction, pancreatitis, or a serious genital or urinary infection.

Contraindications

• Do not use in patients with hypersensitivity to empagliflozin, linagliptin, or any formulation ingredient.
• Not indicated for treatment of type 1 diabetes or diabetic ketoacidosis.
• Avoid use in patients receiving dialysis or with severe kidney impairment when glycemic benefit is not expected.
• Use caution in patients with a history of pancreatitis, recurrent urinary or genital infections, dehydration, low blood pressure, or significant liver or kidney disease.
• Temporarily discontinue and seek medical advice during prolonged fasting, major surgery, or serious acute illness when ketoacidosis risk may increase.

Precautions & Warnings

• Insulin and sulfonylureas may increase the risk of hypoglycemia; dose adjustment may be required.
• Diuretics and other medicines that lower blood pressure may increase dehydration or low blood pressure.
• Strong enzyme inducers such as rifampicin may reduce linagliptin exposure and glucose-lowering effect.
• Other medicines affecting kidney function or fluid balance require medical review.
• Alcohol may increase dehydration and may contribute to metabolic complications; avoid excessive alcohol intake.

Pregnancy

• Use during pregnancy is generally not recommended unless specifically prescribed after medical assessment.
• Empagliflozin should generally be avoided during the second and third trimesters because of potential effects on the developing kidneys.
• Breastfeeding is generally not recommended during treatment because it is unknown whether the medicine passes into human milk and potential infant kidney effects are a concern.
• Inform the doctor if pregnant, planning pregnancy, or breastfeeding.